Parhelia Biosciences

Executive Summary

Parhelia Biosciences is a San Diego-based biotechnology company addressing the critical bottleneck in spatial biology: the complexity and irreproducibility of manual sample preparation for high-plex tissue analysis. Its flagship product, the Spatial Station, is a benchtop instrument that automates multi-step protocols for assays such as multiplexed immunofluorescence, in situ hybridization, and CODEX/PCF. By standardizing workflows, the platform reduces reagent waste, enhances reproducibility, and frees researchers to focus on data interpretation. As spatial biology gains traction in oncology and diagnostics, Parhelia’s automation solution positions it to capture a growing market need for scalable, reliable tools.

Upcoming Catalysts (preview)

• Q3 2026Commercial launch of Spatial Station (version 2.0 with expanded assay compatibility)70% success
• Q4 2026Strategic partnership with a top-tier cancer research center or CRO60% success
• Q2 2026Series A funding round to scale production and sales50% success